BCAN's $1 million Continuity Grant supports bladder cancer research projects impacted by federal funding terminations, ensuring continued progress in the field. Eligible projects include basic, ...

On Saturday, August 2, 2025, Northwestern University is hosting a course titled "Advances in Genitourinary Robotic Reconstruction." In this video, Ziho Lee, MD, the course director and assistant ...

Key Takeaways Hamlet BioPharma is preparing to initiate a phase 3 trial of Alpha1H for NMIBC, following a successful FDA meeting. Alpha1H received fast track designation, allowing for accelerated ...

CMS issued a permanent HCPCS code for Gozellix, effective October 1, 2025, aiding billing and reimbursement processes. Gozellix, approved in March 2025, targets prostate cancer patients with suspected ...

In this landmark episode of Pearls & Perspectives, host Amy Pearlman, MD, sits down with one of the world’s foremost experts in sexual medicine, John P. Mulhall, MD, of Memorial Sloan Kettering Cancer ...

A panelist discusses how the choice between microformulation abiraterone and off-label low-dose regimens is often dictated by cost and insurance coverage rather than purely clinical considerations.

An expert would summarize that bladder cancer management is evolving from traditional radical surgery toward more personalized, less invasive approaches—highlighting promising therapies like Terra-002 ...